title: [Correlations between working memory effectiveness and depression levels after pharmacological therapy].
abstract: OBJECTIVE
  The goal of the study was to identify possible associations between spatio-visual performance and verbal working memory, evaluated on admission, with the remission degree, assessed by the HDRS after 8-week pharmacotherapy with SSRI in a group of patients with depression.
  
  
  METHODS
  141 subjects were examined (patients with depressive disorders, DD: n = 86, healthy subjects, CG: n = 55). TMT and the Stroop Test were used. Results. CG obtained higher results vs. DD-I patients (the evaluation started on the therapy onset) in the Stroop Test, RCNb/time (p < 0.001), NCWd/time (p < 0.001), NCWd/errors (p < 0.001), TMT B/time (p = 0.009). CG demonstrated higher results than DD-II patients (following eight weeks of pharmacological treatment) in the Stroop Test, RCNb/time and NCWd/time (p < 0.001). Compared to DD-I group, DD-II group achieved better results in the Stroop Test, NCWd/time (p = 0.03), NCWd/errors (p < 0.001), TMT, A (p < 0.001), B (p <0.001). The lowest performance levels in the Stroop Test, NCWd/time (p = 0.02), NCWd/errors (p = 0.04) and in TMT, A/time (p = 0.01), may have been related to the highest depression levels after pharmacological treatment.
  
  
  CONCLUSIONS
  1. Depressive disorders are associated with deteriorated efficiency of visual and verbal working memory. 2. Antidepressant treatment resulted in improved of visual and verbal working memory. 3. The better performance in the Stroop Test and in TMT on the first day of treatment may have influenced the noted reduction in severity of depressive symptoms after treatment with SSRI.
authors.affiliation: Klinika Psychiatrii Doroslych UM w Lodzi Kierownik.
authors.forename: Monika
authors.initials: M
authors.lastname: Talarowska
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Zboralski
authors.forename: Piotr
authors.initials: P
authors.lastname: Gałecki
mesh_terms: D000328:Adult; D000928:Antidepressive Agents / Q000627:therapeutic use*; D003071:Cognition / Q000187:drug effects; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008570:Memory, Short-Term / Q000187:drug effects*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D012307:Risk Factors; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D057190:Stroop Test; D014145:Trail Making Test; D016896:Treatment Outcome; D014796:Visual Perception / Q000187:drug effects*; D055815:Young Adult
chemical_list: D000928:Antidepressive Agents